Investors
Presentations & Reports 2020
For investor-related information please contact Ronn Bechler at Automic Group
Ph: +61 (0) 400 009 774 E: ronn.bechler@automicgroup.com.au
https://www.youtube.com/watch?v=to0cJZkeXNM
Proactive – Zelira Therapeutics forms exclusive licensing deal to distribute its HOPE products in Washington DC
Zelira Therapeutics forms exclusive licensing deal to distribute its HOPE products in Washington DC
December 18, 2020
https://www.youtube.com/watch?v=eipQrkRxw_0
Proactive – Zelira Therapeutics and Emyria team up for ‘disruptive’ autism spectrum disorder trial
Some excerpt
November 9, 2020
https://clients3.weblink.com.au/pdf/ZLD/02296985.pdf
Investor Presentation – Non-Deal Roadshow
October 22, 2020
https://zeliratx.com/presentations/ZLD_Presentation_ASX_Small_Med_Cap_Conference_Sept_20.pdf
ASX Small and Mid-Cap Conference
Presentation – ASX Small and Mid-Cap Conference
October 9, 2020
https://www.youtube.com/watch?v=HxPAk4ce-DI
Proactive – ASX Small and Mid-Cap Conference
September 9, 2020
https://www.youtube.com/watch?v=h2xPZSc3g8w
Proactive – CEO Investor Sessions
August 11, 2020
Investor Presentation
July 8, 2020
https://zeliratx.com/presentations/Investor Presentation - Logistics for Benzinga conference.pdf
Investor Presentation – Logistics for Benzinga conference
June 1, 2020
https://zeliratx.com/presentations/Presentation_Website_010520.pdf
Investor Presentation – Non-deal Roadshow
May 1, 2020
https://zeliratx.com/presentations/Insomnia-Phase-2-Clinical-Trial-Presentation.pdf
Insomnia Phase 2 Clinical Trial Presentation
April 8, 2020
https://zeliratx.com/presentations/Zelira-Therapeutics-Trial-Results-10005625-080420.mp3
Investor Teleconference: Insomnia Trial Meets Primary and Secondary Endpoints
April 8, 2020
https://www.youtube.com/watch?v=FWsnh-xEENg
Proactive Interview – Zelira Therapeutics releases interim data for Phase II clinical trial for insomnia
February 20, 2020
https://www.youtube.com/watch?v=FWsnh-xEENg
Proactive Interview – Zelira Therapeutics releases interim data for Phase II clinical trial for insomnia
February 2, 2020